Mucosal Healing in Ulcerative Colitis Patients Treated With Vedolizumab: Patient-, Dose-, or Duration-Dependent?

J Crohns Colitis. 2017 Oct 27;11(11):1403-1404. doi: 10.1093/ecco-jcc/jjx074.
No abstract available

Publication types

  • Letter

MeSH terms

  • Adult
  • Antibodies, Monoclonal, Humanized / administration & dosage
  • Antibodies, Monoclonal, Humanized / adverse effects
  • Colitis, Ulcerative* / diagnosis
  • Colitis, Ulcerative* / drug therapy
  • Colonoscopy / methods*
  • Dose-Response Relationship, Drug
  • Drug Monitoring / methods
  • Female
  • Gastrointestinal Agents / administration & dosage
  • Gastrointestinal Agents / adverse effects
  • Humans
  • Intestinal Mucosa / diagnostic imaging
  • Intestinal Mucosa / drug effects
  • Male
  • Middle Aged
  • Portugal
  • Time Factors
  • Treatment Outcome

Substances

  • Antibodies, Monoclonal, Humanized
  • Gastrointestinal Agents
  • vedolizumab